Videos

Early results from the LINKER-MM1 trial show high response rates for linvoseltamab, offering new hope for newly diagnosed patients.

Early results from the LINKER-MM1 trial reveal promising response rates for linvoseltamab in newly diagnosed multiple myeloma patients, with manageable side effects.

Focus on payer dynamics, cost, prior authorization processes, and the logistical aspects of transitioning patients from factor-based to nonfactor therapies, including adherence and at-home treatment implications.

This segment interprets PHAROS results in a real-world clinical context, emphasizing that despite excellent frontline activity, long-term survival remains limited by complex resistance patterns and post-progression challenges.

This segment reviews the strong efficacy findings from PHAROS—particularly the ~30-month median PFS in frontline patients—positioning the regimen as a major advancement in BRAF-mutant NSCLC therapy.

This segment introduces the PHAROS trial design and rationale, describing how its dual-cohort structure and long follow-up provide foundational evidence for encorafenib + binimetinib in this rare population.

This segment explains the clinical significance of BRAF V600E–mutant NSCLC and highlights why early comprehensive genomic profiling is essential for identifying patients who benefit most from targeted BRAF/MEK inhibition.

Detailed discussion of Fitusiran, Marstacimab, and Concizumab, their mechanisms of action, differentiation from factor replacement, and highlights from key clinical trials (BASIS, ATLAS, Explorer 8).

Elacestrant significantly improved progression-free survival and maintained a manageable safety profile, especially benefiting patients with ESR1-mutated tumors.

Mark Nestor reveals groundbreaking insights on botulinum toxin's evolving science, enhancing its efficacy and expanding its medical applications in dermatology.

Discover how botulinum toxin injections in the glabella affect brain function, enhancing mood by altering emotional feedback from frowning.

Expert discusses how, despite its importance, albuminuria screening remains underutilized, and improving adherence to dual testing can transform early CKD detection.

Exploration of the emergence of nonfactor treatment classes, explaining how these agents function independently of missing clotting factors and their relevance to patient convenience, dosing, and efficacy.

Among chemotherapy-naive patients, elacestrant extended median progression-free survival compared with standard therapy, particularly in ESR1-mutated cases.

The EMERALD study carries significant implications across multiple stakeholders in ER+/HER2- metastatic breast cancer.

Expert discusses how understanding and promoting awareness of CKD stages enables earlier intervention and better management of disease progression and cardiovascular risk.

A historical perspective on traditional factor replacement therapies, tracing their development, successes, and ongoing limitations such as short half-life, infusion requirements, and inhibitor formation.

Expert discusses how the high prevalence of undiagnosed CKD creates a significant clinical and financial burden that can be alleviated through earlier detection and intervention.

Milliman’s Jennifer Cruz says plans are losing rebates because of steep price discounts negotiated under the Inflation Reduction Act. but that they need to be sure that renegotiation of rebate guarantees doesn’t get too broad.

Pharmacy benefit managers are approaching health plans with value-based contracts that consider lower costs on the medical benefit of the insurance, says Jennifer Cruz of Milliman.

AI and virtual care revolutionize dermatology, enhancing melanoma detection, expanding patient access and improving efficiency in clinical practices.

Efficacy analyses from the EMERALD trial demonstrated that the oral SERD elacestrant improved progression-free survival, particularly in patients harboring ESR1 mutations, highlighting its potential to overcome endocrine resistance.

Stratification in clinical trials, such as by ESR1 mutation status, presence of visceral metastases, and prior fulvestrant exposure, mirrors key considerations in real-world management of ER+/HER2- metastatic breast cancer.

Nearly all women experience a decrease in libido as they go through perimenopause and menopause, but it remains unaddressed

Fulton County leaders tackle healthcare disparities by forming partnerships and enhancing access, aiming for equitable health solutions in Georgia. Pamela Roshell, Ph.D., and LaTrina Foster spoke with Managed Healthcare Executive in this second part of a two-part video interview series.

An expert discusses how the CLEAR Outcomes trial data demonstrated that bempedoic acid effectively reduces cardiovascular events by 13% in nearly 14,000 statin-intolerant patients over 4.9 years with excellent tolerability, while long-term data from PCSK9 inhibitor studies such as the FOURIER trial show sustained safety and efficacy over five to eight years with the principle that “lower for longer is better,” as patients who started treatment earlier maintained cardiovascular protection advantages that late-starters could never catch up to despite achieving similar LDL reductions.

Fulton County, Georgia addresses health disparities through innovative partnerships, expanding access to care and a holistic approach to behavioral health services, according to county experts LaTrina Foster and Pamela Roshell, Ph.D., in this first part of a two-part video series.

Although people are living longer with HIV, patients must still grapple with survivors’ remorse and the challenges of growing older within an ageist society.

Milliman's Jennifer Cruz, Pharm.D., said health plans should be able to track rebates to their book of business and have strong audit rights.

The EMERALD trial enrolled patients with ER+/HER2- metastatic breast cancer who had progressed on prior endocrine therapy, including mandatory exposure to a CDK4/6 inhibitor, reflecting a modern and clinically relevant population.